Recommended Vaccines for a 23-Year-Old Male
A 23-year-old male should receive Tdap (if not previously given as an adult), MMR (if born in 1957 or later without evidence of immunity), varicella (2 doses if no evidence of immunity), annual influenza vaccine, and may receive HPV vaccine if not previously vaccinated, though routine HPV vaccination for males is recommended only through age 21.
Core Routine Vaccinations
Tetanus, Diphtheria, Pertussis (Tdap/Td)
- One dose of Tdap is essential if not previously received as an adult, followed by Td booster every 10 years 1
- If the primary vaccination series was never completed, start or complete the 3-dose series with at least one dose being Tdap
Measles, Mumps, Rubella (MMR)
- At least 1 dose of MMR is required for adults born in 1957 or later without evidence of immunity 1
- Evidence of immunity includes: documentation of vaccination, laboratory evidence of immunity, or birth before 1957 (though this doesn't apply to a 23-year-old)
- A second dose may be indicated for certain high-risk groups (healthcare workers, international travelers, college students)
Varicella (Chickenpox)
- Two doses of varicella vaccine are needed if there is no evidence of immunity 1
- Evidence of immunity includes: documentation of 2 doses at least 4 weeks apart, U.S.-born before 1980 (not applicable here), history of varicella disease verified by a healthcare provider, or laboratory evidence of immunity
- This is particularly important for college students, as they are specifically mentioned as a high-risk group for exposure 1, 2
Influenza
- Annual influenza vaccination is recommended for all adults 3
- Should be given seasonally each year
Age-Specific Considerations
Human Papillomavirus (HPV)
- HPV vaccination is optional but may be given through age 26 for males 1
- The routine recommendation for males is through age 21; ages 22-26 represent a permissive recommendation ("may be vaccinated")
- Strongly recommended through age 26 for men who have sex with men or immunocompromised individuals 1
- Consists of a 3-dose series if initiated
Meningococcal Vaccines
- MenACWY booster is recommended if the initial adolescent dose was given before age 16 3, 4
- MenB vaccine may be considered under shared clinical decision-making for ages 16-23, though this is not a routine recommendation 4, 5
- College students living in dormitories have increased risk and should particularly consider meningococcal vaccination
Vaccines NOT Indicated at This Age
Zoster (Shingles)
- Not recommended until age 60 years (or 50 years at earliest) 1
Pneumococcal
- Not routinely recommended for healthy 23-year-olds without specific risk factors 3
Important Clinical Pitfalls
Common mistake: Assuming that because someone is young and healthy, they don't need vaccines. The 2014 ACIP guidelines specifically emphasize that college students are a high-risk group for varicella and meningococcal disease due to close living quarters 1.
HPV confusion: Many clinicians incorrectly believe HPV is routinely recommended through age 26 for all males. The evidence is clear: routine recommendation is only through age 21 for males; ages 22-26 is permissive ("may be vaccinated") unless the patient is MSM or immunocompromised 1.
Documentation gaps: Don't accept patient recall alone for measles, mumps, rubella, or varicella immunity. The guidelines specify that provider-diagnosed disease or laboratory evidence is required 1.
Practical Approach
- Review vaccination records for Tdap, MMR, varicella, and meningococcal vaccines
- Assess immunity status through documentation or serology if records are unavailable
- Prioritize catch-up vaccination for any missing routine vaccines (Tdap, MMR, varicella)
- Offer annual influenza vaccine based on season
- Discuss HPV vaccination if not previously completed, emphasizing the permissive nature of the recommendation at age 23
- Consider meningococcal booster if living situation or other risk factors warrant it
The most recent comprehensive guideline 3 from 2024 maintains these core recommendations while adding newer vaccines (COVID-19, RSV, mpox) that should be considered based on current epidemiology and individual risk factors.